[1] |
张荣芳, 钱磊, 常明杰, 等. 血清HBV RNA在慢性乙型肝炎抗病毒治疗过程中的动态变化及其临床意义[J]. 天津医科大学学报,2021,27(5):520-523.
|
[2] |
张玲, 郑荣, 何三军, 等. 慢性乙型肝炎患者HBV-DNA载量、肝功能指标与免疫学标志物的相关性研究[J]. 检验医学与临床,2020,17(22):3348-3350.
|
[3] |
刘潘婷, 向瑜, 周红菊, 等. HBeAg和HBeAb共同阳性CHB患者血清HBV RNA表达水平及检测意义[J]. 检验医学与临床,2022,11(21):2885-2889.
|
[4] |
D’souza S, Lau KC, Coffin CS, et al. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma[J]. World J Gastroenterol, 2020,6(38):5759-5783.
|
[5] |
Yeh, Chau-Ting. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy[J]. Antivir Ther,2010,15(3 Part B):471-475.
|
[6] |
Wu C, Li B, Zhang X, et al. Complementation of wild-type and drug-resistant hepatitis B virus genomes to maintain viral replication and rescue virion production under nucleos(t)ide analogs[J]. Virol Sin, 2019,34(4):377-385.
|
[7] |
Colledge D, Soppe S, Yuen L, et al. Stop codons in the hepatitis B surface proteins are enriched during antiviral therapy and are associated with host cell apoptosis[J]. Virology,2017,501(Complete): 70-78.
|
[8] |
Colagrossi L, Hermans LE, Salpini R, et al. Immune-escape mutations and stop codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe[J]. Bmc Infect Dis,2018,18:251.
|
[9] |
刘妍, 徐东平. 再谈乙型肝炎病毒反转录酶区/表面抗原区基因变异的临床发生特点及意义[J]. 解放军医学杂志,2018,43(5):361-366.
|
[10] |
Zhang X, Chen X, Wei M, et al. Potential resistant mutations within HBV reverse transcriptase sequences in nucleos(t)ide analogues-experienced patients with hepatitis B virus infection[J]. Sci Rep, 2019,9(1):8078.
|
[11] |
中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J/CD]. 中华实验和临床感染病杂志(电子版),2019,13(6):441-466.
|
[12] |
张小曼, 徐涛, 许正锯. 闽南地区核苷(酸)类药物经治的乙型肝炎患者乙型肝炎病毒基因型与逆转录酶区耐药突变特点[J/CD]. 中华实验和临床感染病杂志(电子版),2019,13(4):293-299.
|
[13] |
Jang JW, Yoo SH, Kwon JH, et al. Serum hepatitis B surface antigen levels in the natural history of chronic hepatitis B infection[J]. Aliment Pharmacol Ther,2011,34(11-12):1337-1346.
|
[14] |
Matsumoto A , Tanaka E , Morita S, et al. Changes in the serum level of hepatitis B virus (HBV) surface antigen over the natural course of HBV infection[J]. J Gastroenterol,2012,47(9):1006-1013.
|
[15] |
Liu MH, Chen QY, Harrison TJ, et al. The correlation between serum HBsAg levels and viral loads depends upon wild-type and mutated HBV sequences rather than the HBeAg/anti-HBe status[J]. J Med Virol,2015,87(8):1351-1360.
|
[16] |
申红玉, 张宏宇, 陈敏, 等. 乙型肝炎患者不同突变谱的乙肝表面抗原水平变化[J]. 实用医学杂志,2020,36(3):344-348.
|
[17] |
Shen H, Chen C, Ye C, et al. Mutations in reverse transcriptase region of HBV affect Hepatitis B surface antigen titers and its correlation with HBV DNA[J]. J Infect Dev Ctries,2019,13(11):1062-1067.
|
[18] |
黄碧霞, 刘妍, 思兰兰, 等. 乙型肝炎病毒反转录酶区耐药突变患者HBsAg主要亲水区免疫逃逸相关突变研究[J]. 解放军医学杂志,2020,45(5):526-530.
|
[19] |
赵丽, 李晓东, 陈荣娟, 等. 乙型肝炎病毒rtA181T耐药相关突变引起的sW172终止与非终止突变的临床发生特点及表型差异分析[J]. 解放军医学杂志,2018,43(5):373-379.
|
[20] |
段金伟, 张鹏, 张婧, 等. 慢性HBV感染人群血清HBsAg清除的影响因素及其临床意义[J]. 临床肝胆病杂志,2021,37(7):1682-1685.
|
[21] |
Martinot-Peignoux M, Carvalho-Filho R, Lapalus M, et al. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-navie, E antigen positive patients[J]. J Hepatol, 2013,58(6):1089-1095.
|
[22] |
吕新建, 石贵福, 王合群. HBsAg低反应性乙肝患者HBeAg表达与HBV基因型, DNA载量的关系[J]. 河南医学研究,2022,9(13):3339-3342.
|
[23] |
Xiang Y, Yang Y, Chen P, et al. Analysis of serum hepatitis B virus RNA levels among HBsAg and HBsAb copositive patients and its correlation with HBV DNA[J]. Medicine (Baltimore),2021,100(40): e27433.
|
[24] |
李彦霖, 王妍, 周颖琼, 等. 慢性乙型肝炎免疫耐受期的抗病毒治疗:系统综述[J]. 临床肝胆病杂志,2021,37(6):1282-1287.
|
[25] |
石璐瑶, 郭文敏, 李红. 表面抗原定量在慢性乙型肝炎抗病毒治疗中的研究现状[J]. 安徽医药,2022,26(9):1701-1705.
|
[26] |
张学平, 邵宏伟, 王静. 不同阶段慢性HBV感染患者血清HBsAg定量值与血清HBV DNA相关性分析[J]. 标记免疫分析与临床,2021,28(1):51-54.
|